Tenpoint Therapeutics secures $235 million through Series B financing led by Janus Henderson to accelerate commercialization of YUVEZZI™.
Amount Raised
$235 Million
Round Type
Series B
Investors
Description
Tenpoint Therapeutics, a commercial biotechnology company, has raised $235 million through Series B financing and a credit facility. The Series B round saw participation from prominent investors including Janus Henderson and EQT Nexus. The funding will support the launch of YUVEZZI™, the first dual-agent eye drop for presbyopia. CEO Henric Bjarke expressed confidence in the product's potential to meet the needs of millions affected by this condition.
Quick answer
Tenpoint Therapeutics raised $235 Million in a Series B round, dated January 29, 2026. Investors: AdBio, Wille, Ad Bio, Sofinnova Partners, EQT Life Sciences, British Business Bank, Hillhouse and EQT Nexus.
- How much did Tenpoint Therapeutics raise?
- Tenpoint Therapeutics raised $235 Million in a Series B round on January 29, 2026.
- Who invested in Tenpoint Therapeutics?
- AdBio, Wille, Ad Bio, Sofinnova Partners, EQT Life Sciences, British Business Bank, Hillhouse and EQT Nexus are named as investors in this round.
- What does Tenpoint Therapeutics do?
- Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases, bringing together the global experts..
- Where is Tenpoint Therapeutics based and how big is it?
- Fundz records about 25 employees.
- Who are the decision-makers at Tenpoint Therapeutics?
- Fundz holds 1 contact at Tenpoint Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Tenpoint Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Combat Medical raised $3.5M (Series A) on March 12, 2026.
- GenSight Biologics raised $2M (Post-IPO Equity) on March 10, 2026.
- Cognito Therapeutics raised $105M (Series C) on March 5, 2026.
- Prolium Bioscience raised $50M (Series A) on March 5, 2026.
- NexCure raised $19M (Series A) on March 5, 2026.
- Os Therapies raised $2M on March 4, 2026.
Who to call at Tenpoint Therapeutics, and when
A new round usually means Tenpoint Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Tenpoint Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Tenpoint Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Tenpoint Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Tenpoint Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansTenpoint Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.